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Role of multidrug-
resistant pathogens in 
health-care-associated 
pneumonia
We read with interest Santiago Ewig 
and colleagues’ article1 discussing 
the validity of a new classiﬁ cation 
scheme for pneumonia, including for 
health-care-associated pneumonia 
(HCAP). The investigators reviewed 
the available evidence, including 
our 2009 study.2 They conclude that 
this study does not prove much 
more than that patients admitted 
to hospital within 180 days have a 
similar mortality as patients with 
hospital-acquired pneumonia, and 
that the key issue of HCAP—excess 
mortality due to drug-resistant 
pathogens—was not assessed. Here 
we present microbiological data from 
this prospective study, which was 
undertaken in Italy between January 
and July, 2007.
Microbiological data were culture 
results from the ﬁ rst 5 days after 
admission to hospital, or within 5 days 
of diagnosis with pneumonia. An 
aetiological diagnosis was deﬁ nitive 
if one of the following criteria were 
met: (1) blood cultures yielded a 
bacterial pathogen (in the absence 
of an apparent extrapulmonary 
focus); (2) pleural ﬂ uid and cultures 
of transthoracic needle aspiration 
yielded a bacterial pathogen; 
(3) a respiratory sample that was 
representative of the lower respiratory 
tract (ﬁ beroptic bronchoscopy with 
protected catheter) yielded a bacterial 
pathogen; (4) isolation of Legionella 
pneumophila in sputum, or detection 
of L pneumophila serogroup 1 or 
pneumococcal antigen in urine; (5) an 
increase of four times in the antibody 
titre, or seroconversion for atypical 
pathogens. An aetiological diagnosis 
was regarded as presumptive when 
a predominant microorganism was 
isolated from a purulent sample 
(more than 25 polymorphonuclear 
leucocytes and fewer than ten 
squamous cells per low-power ﬁ eld 
[original magniﬁ cation×10]) with 
compatible ﬁ ndings from Gram stains.
Overall, an aetiological diagnosis 
was obtained in 22·4% of patients 
(95% CI 20·2–24·6). 28·4% (23·4–33·4) 
had a presumptive microbiological 
diagnosis, and 71·6% (66·6–77·6) 
a deﬁ nitive diagnosis. Bacteraemia 
occurred in six patients with HCAP 
(Streptococcus pneumoniae in two, 
Staphylococcus aureus in three, and 
Escherichia coli in one), in four patients 
with hospital-acquired pneumonia 
(S aureus in three, and E coli in one), and 
in seven patients with community-
acquired pneumonia (S pneumoniae in 
four, E coli in two, and Pseudonomas 
aeruginosa in one). No statistically 
signiﬁ cant diﬀ erences were noted 
in the rates of bacteraemia between 
the three groups. A microbiological 
documentation was more frequently 
obtained in patients with HCAP 
(31·1%, 95% CI 19·7–42·5) than in 
those with community-acquired 
(18·4, 11·9–24·8) or hospital-acquired 
pneumonia (24·5, 9·2–39·8).
The distribution of pathogens 
varied among the three pneumonia 
categories (table), with S aureus 
predominating in the HCAP and 
hospital-acquired pneumonia groups, 
and S pneumoniae in the community-
acquired group. The rate of meticillin 
resistance among S aureus isolates 
was 37·5% in the community-acquired 
group, 63·6% in the HCAP group, 
and 50% in the hospital-acquired 
group. These results seem to conﬁ rm 
the role of potentially multidrug 
resistant pathogens such as S aureus, 
P aeruginosa, and other Gram-negative 
bacilli, in patients with HCAP. As noted 
by other investigators,3–5 patients 
with HCAP have a higher incidence 
of multidrug-resistant bacteria 
and, consequently, an increased 
likelihood of receiving inappropriate 
antibacterial therapy at the start.2 This 
factor seems to be crucial in explaining 
the increased mortality recorded for 
HCAP.
In our study, features of patients with 
community-acquired pneumonia and 
HCAP were not substantially diﬀ erent 
in terms of median age, presence of 
comorbidities, or immunosuppression. 
Thus, the proposed classiﬁ cation of 
community-acquired pneumonia 
based on mean age or functional status 
is questionable. The review by Ewig 
and colleagues underestimates the 
value of clinical and microbiological 
studies undertaken in diﬀ erent areas 
of the world (Europe, Japan, and the 
USA). Future prospective clinical 
trials are needed to delineate the 
pathogens and risk factors associated 
with HCAP. However, the available 
evidence supports HCAP as a new 
category of pneumonia, which is 
distinct from community-acquired 
CAP
n=41
HCAP
n=28
HAP
n=12
p value
Staphylooccus aureus 7 (17·1%) 11 (39·3%) 6 (50·0%) 0·034
Streptococcus pneumoniae 18 (43·9%) 2 (7·1%) 0 <0·001 
Gram-negative bacteria
Pseudonomas aeruginosa 4 (9·7%) 2 (7·1%) 2 (16·7%) 0·65
Enterobacteriaceae and other Gram negative bacilli 5 (12·2%) 9 (32·1%) 2 (16·7%) 0·11
Haemophilus inﬂ uenzae/parainﬂ uenzae 1 (2·4%) 1 (3·6%) 1 (8·3%) 0·68
Atypical bacteria
Mycoplasma, Chlamydia, Legionella spp 3 (7·3%) 1 (3·6%) 1 (8·3%) 0·77
Others*† 3 (7·3%) 2 (7·1%) 0 0·69
Data are number (%) of patients. CAP=community-acquired pneumonia. HCAP=health-care-associated pneumonia. HAP=hospital-acquired 
pneumonia. *CAP: one atypical mycobacterium, one Aspergillus fumigatus, and one Mycobacterium tuberculosis; †HCAP: one atypical mycobacterium, 
one M tuberculosis. 
Table: Frequency of microbial pathogens associated with community-acquired, health-care-associated, or hospital-acquired 
pneumonia
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immediately. Moreover, caution 
should be taken when results of 
MRSA cultures are interpreted. In the 
absence of quantitative cultures, only 
bacteraemic episodes, or positive 
cultures from sites that are normally 
sterile, would be deﬁ nite evidence for 
infection. Pseudomonas aeruginosa was 
even slightly higher in community-
acquired than in hospital-acquired 
pneumonia (9·7% vs 7·1%), and 
Gram-negative enterobacteriaceae 
were more frequent in HCAP than 
in hospital-acquired pneumonia 
(32·1 vs 16·7). The unusually high 
rates of P aeruginosa and Gram-
negative enteric bacilli in community-
acquired pneumonia add to our 
reservations about the validity 
of the microbiological data. The 
investigators do not provide data for 
resistance patterns of P aeruginosa 
and Gram-negative enteric bacilli; we 
cannot therefore know the true rate 
of multidrug-resistant pathogens, 
although they claim to have identiﬁ ed 
an excessive rate of multidrug 
resistance in patients meeting the 
deﬁ nition for HCAP.
Venditti and colleagues try to 
convince us that HCAP is diﬀ erent 
from community-acquired pneumonia 
with just 22 patients (11 with MRSA, 
two with P aeruginosa, nine with 
pneumonia, both epidemiologically 
and microbiologically.
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We appreciate that Mario Venditti 
and colleagues now present their 
microbiological data for the Italian 
multicentre study of community-
acquired, hospital-acquired, and 
health-care-assisted pneumonia 
(HCAP).1 They claim that these 
data support the idea that HCAP is 
distinct from community-acquired 
pneumonia, a view with which 
we disagree. Microbiological data 
included samples from patients 
from the ﬁ rst 5 days after admission 
to hospital or within 5 days of 
diagnosis with pneumonia. Standards 
generally indicate that samples 
should be obtained at diagnosis. 
Results from samples obtained 
after diagnosis carry a signiﬁ cant 
risk for representing nosocomial 
colonisation or superinfection, 
particularly after introduction of 
antimicrobial treatment. This risk 
is a concern, particularly in view of 
the failure to undertake quantitative 
cultures of respiratory samples 
retrieved bronchoscopically. Overall, 
the diagnostic yield was low, with an 
aetiological diagnosis obtained in 
only 81 patients (22·4%). Of these 81, 
two had Mycobacterium tuberculosis 
and two had non-tuberculous 
mycobacteria, which are not usually 
regarded as pathogens of pneumonia. 
Of the patients with HCAP, only 28 had 
an aetiological diagnosis (26 excluding 
mycobacteria), which preclude valid 
conclusions about the aetiology of the 
populations studied.
The microbial range is statistically 
signiﬁ cant for only Streptococcus 
pneumoniae, which were more 
frequent in community-acquired 
pneumonia, and for meticillin-resistant 
Staphylococcus aureus (MRSA), which 
were more common in health-care-
associated and hospital-acquired 
pneumonia. However, reported rates 
of MRSA are excessively high, reaching 
17·1% even in community-acquired 
pneumonia, and if representative, 
would need guidelines of community-
acquired pneumonia to be revised 
Classiﬁ cation of pneumonia on the basis of where it was acquired is under debate
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